Join
Live feed
·
INSIDERFilingvia Quantisnow
Day One Biopharmaceuticals Inc. logo

Head of Research and Dev. Vasconcelles Michael returned 4,397 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)

ByQuantisnow·Wall Street's wire, on your screen.
DAWN· Day One Biopharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DAWN (Day One Biopharmaceuticals Inc.) and more on Quantisnow.

Head of Research and Dev. Vasconcelles Michael returned 4,397 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation) | Quantisnow